Hospice M&A · April 2026 · 9-Minute Read

In April 2026, federal regulators suspended Medicare payments to 447 hospices and 23 home health organizations over more than $600 million in alleged fraudulent billing the largest coordinated hospice payment-suspension action on record. If you own a clean, well-run hospice agency, the question on your kitchen table tonight is simple: does this make my agency more valuable, or less?

The honest answer, as of April 2026: if your books are clean, your length-of-stay sits within MedPAC norms, you are not on the Special Focus Program (SFP) list, and your HOPE submissions are accurate this is the strongest seller’s market for clean hospice in five years. The crackdown isn’t a reason to wait. For documentably clean operators, it is the reason to move now, before deal pipelines clog and the diligence bar ratchets even higher.

This guide is built for you the hospice founder or operator weighing a valuation, an exit, or a recapitalization in 2026. We will cover what your agency is actually worth in today’s market, why the April 2026 fraud reset is shifting buyer behavior, the seven-step process Vallexa Advisors uses to sell hospices confidentially, and the specific things you can do in the next 90 days to widen the gap between your sale price and the price your less-prepared neighbor will get.

What the April 2026 hospice crackdown actually means

The short answer: Federal regulators just delivered the biggest hospice payment-suspension action in Medicare history, buyers are sharpening diligence in response, and the gap between what a clean hospice will sell for and what a problem hospice will sell for is widening fast.

According to Home Health Care News, CMS, the OIG, and the UPIC contractors coordinated the simultaneous suspension of Medicare payments at 447 hospices and 23 home health organizations across multiple states, citing more than $600 million in alleged fraudulent billing. That single number reframes the M&A market. Buyers’ Quality of Earnings teams are now flagging the same indicators that triggered the suspensions anomalous length-of-stay distributions, GIP overuse, ghost-patient signals, kickback-shaped referral structures and they are walking away from any deal where those indicators appear.

A second HHCN report on Congressional testimony in April 2026 warned that fraud actors who entered hospice in 2018–2023 are now rotating into home health as hospice enforcement tightens. For dual-line operators (hospice + home health), this matters: buyers want to see clean separation between the lines, separate compliance programs, and clean intercompany economics. A muddled dual-line operation now takes a complexity discount; a clean one keeps the premium.

And a third HHCN piece on the expanding enforcement net documents how scrutiny is broadening from hospices themselves to billing companies, medical directors, and referral-source kickback structures. Translation for owners considering an exit: pre-LOI fraud-risk attestations are now standard, and any documentation gap in those areas can stall or kill a deal that should have closed in 90 days.

The crackdown isn’t a market signal to wait. It’s a market signal to get clean and get to market before the buyer pool narrows further.

What is my hospice worth in 2026?

Short answer: Most clean independent hospices in April 2026 are trading at 5x–8x adjusted EBITDA, or roughly 0.7x–1.4x trailing revenue. Premium multi-state platforms with $20M+ revenue can clear 8x–10x. SFP-flagged or fraud-adjacent agencies often sell at 2x–4x or in asset-only structures and many are unsalable until cleared.

The longer answer: hospice valuation is not a single multiple. It is a stack of factors, each of which moves your number up or down. The same $4M-EBITDA hospice can be worth $20M to one buyer and $32M to another based on the items below.

Hospice valuation multiples by ADC tier (April 2026)

Profile	Average Daily Census	Adjusted EBITDA Multiple	Revenue Multiple
Sub-scale independent	30–60 ADC	3.5x – 5x	0.5x – 0.8x
Established independent	60–125 ADC	5x – 7x	0.7x – 1.1x
Regional standout	125–300 ADC	6.5x – 8.5x	1.0x – 1.3x
Multi-state platform	300+ ADC	8x – 10x+	1.2x – 1.6x
SFP / audit / fraud-adjacent	Any	2x – 4x or asset deal	0.2x – 0.5x

What actually moves your hospice’s multiple

• Average Daily Census (ADC) trajectory. Buyers pay for slope, not just size. A 90-ADC agency growing 12% YoY usually beats a flat 110-ADC agency.
• Length-of-stay distribution. Buyers benchmark against MedPAC and CMS national norms. Outlier LOS too long or too short gets flagged and discounted.
• Payer mix & level-of-care mix. Routine Home Care vs. GIP vs. Continuous vs. Respite. GIP utilization that looks aggressive against peers will sit in the QofE crosshairs.
• Medicare cap exposure. Three years of clean cap reports with no liability or refund history is worth real multiple expansion.
• HOPE submission accuracy & HQRP/STAR performance. Buyers now diligence this directly. Submission rejections and STAR slippage take dollars off the table.
• Referral concentration. No single referral source above 15–20% is the gold standard. Heavy concentration on one hospital or one medical director triggers indemnification reserves.
• Management depth. An agency that runs without the owner trades higher than one that doesn’t. Period.
• Compliance posture. Confirmed not on SFP, no active UPIC review, clean exclusions screening, documented Medical Director FMV these are now pre-LOI attestations.

The “flight to quality” thesis why clean operators win in 2026

Short answer: Every hospice fraud crackdown cycle since 2018 has produced the same M&A pattern. Buyers retreat for one to two quarters, then return with tighter diligence and a higher willingness to pay for clean, audited operators. The April 2026 cycle is the strongest version of this dynamic yet.

Three forces are pushing the same direction: PE-backed platforms have capital they need to deploy, the crackdown just took 447 of your competitors off the buyer’s shopping list, and the new pre-LOI attestation requirements have made it harder for problem operators to dress up for sale. The result: buyers are concentrating their capital on a smaller pool of clean targets, and the headline multiples on those targets are holding up and in some sub-segments, expanding.

That doesn’t mean it is suddenly easy. Diligence cycles are slower. Working-capital pegs are tighter. R&W insurance carriers are excluding more risks than they did a year ago. But for an owner with a clean operation and good documentation, this is a market environment where being prepared is worth real money and being unprepared costs real money.

How to sell a hospice agency: the 7-step Vallexa process

Short answer: Engage a healthcare-only M&A advisor, normalize EBITDA, attest compliance, build the CIM, run a confidential auction to a vetted buyer network, negotiate the LOI, and close the CHOW. Plan for 6–9 months end to end.

1. Build a complimentary, accurate valuation. Start with a no-cost confidential valuation from a healthcare-only advisor. The right number is built on adjusted EBITDA, ADC, payer mix, length-of-stay, HOPE/HQRP performance, and Medicare cap history not on a generic “industry multiple.”
2. Normalize EBITDA and prep the data room. Document add-backs (owner comp, one-time legal, M&A advisory, non-recurring marketing, personal expenses). Prepare three years of statements, a working-capital schedule, and a CapEx history. Assemble the data room before any buyer is contacted.
3. Run a pre-LOI compliance attestation. Confirm SFP status, document UPIC/MAC review history, verify HOPE submission accuracy, produce clean OIG/SAM exclusions screening, and review your Medical Director agreements for FMV and Stark/AKS compliance.
4. Build the Confidential Information Memorandum (CIM). Tell the growth and market story. Quantify the buyer thesis. Document the post-close transition plan — including how long you will stay, what “help” looks like, and what the earnout structure should reward.
5. Run a confidential auction to a vetted buyer network. Approach 25–75 qualified buyers under NDA. Collect Indications of Interest (IOIs). Shortlist for management meetings. Vallexa’s vetted network covers PE-backed platforms, regional consolidators, hospital/health-system home-based-care arms, and independent strategics.
6. Negotiate the LOI and select the buyer. Compare price, structure, earnout, working-capital peg, escrow holdback, indemnification, R&W insurance, and post-close terms. The highest headline price is rarely the highest net price.
7. Close diligence and complete the CHOW. Coordinate Quality of Earnings, legal diligence, and the Medicare 855A Change of Ownership filing through definitive agreements and close. Plan for 60–120 days on the CHOW alone.

This is the same seven-step process Vallexa Advisors runs for every hospice client. We have refined it over more than a decade of hospice and home health transactions, and we update it every quarter as the diligence environment evolves.

Who buys hospice agencies in 2026?

Short answer: The 2026 hospice buyer landscape has four primary archetypes, each with a different pricing logic and a different post-close lifestyle for you.

Buyer type	What they pay for	Typical structure	Your post-close life
PE-backed platform	Scale, ADC growth, leadership depth, geographic fit	Cash + earnout + rollover equity	2–4 year transition; possible second-bite at recap
Regional consolidator	State density, referral relationships, license	Cash + modest earnout	6–18 month transition
Hospital/health-system home-based-care arm	Continuum-of-care, market share, employed referral capture	Cash + retention	1–3 year transition; integration leadership role available
Independent strategic	Single-state add-on, complementary catchment	Cash + small earnout	3–12 month transition

The CHOW timeline and why your sale takes 6–9 months

Short answer: A typical hospice sale runs 6–9 months from advisor engagement to close. The Medicare 855A CHOW filing alone takes 60–120 days. Add 60–90 days when there is active UPIC review, complex corporate structure, or multi-site licensure.

• Months 1–2: Valuation, EBITDA normalization, data room build, CIM drafting, pre-LOI compliance attestation.
• Months 3–4: Confidential buyer outreach, IOIs received, management meetings, LOI negotiation and selection.
• Months 5–6: Quality of Earnings, legal diligence, definitive agreement negotiation, 855A CHOW filing initiated.
• Months 7–9: CMS regional office processing, state license transfers, working-capital peg true-up, escrow setup, close.

The biggest variable is regulatory: a clean compliance file shaves weeks; an open audit adds months. The second biggest variable is corporate hygiene — minute books, cap tables, lease estoppels, contract assignability. Get these right early and the back end of the timeline runs on rails.

Your 90-day pre-sale readiness plan

You don’t need to know whether you’ll sell in 2026 to start preparing. The work below pays off whether you sell next quarter or hold for three more years — and it’s the difference between a 5x deal and a 7x deal.

Days 1–30 — Get the numbers right

• Pull three years of financial statements and reconcile to the G/L and Medicare cost reports.
• Build a normalized EBITDA worksheet with documented add-backs.
• Run a payer-mix and level-of-care analysis by month, by site, for the trailing 24 months.
• Build a Medicare cap exposure schedule for the last three cap years.

Days 31–60 — Get the compliance file clean

• Confirm SFP status. Pull last three surveys with PoCs and close-out letters.
• Document UPIC, ZPIC, RAC, and MAC review history. Address any open items.
• Audit HOPE submissions for accuracy. Resolve any rejected submissions.
• Refresh your Code of Conduct, exclusions screening, and Medical Director FMV documentation.

Days 61–90 — Get advisor-ready

• Engage a healthcare-only M&A advisor for a confidential valuation.
• Build the data room outline. Identify what’s missing and assign owners.
• Draft your post-close transition plan: 0, 6, 12, or 24 months — and what “help” looks like.
• Build a net-proceeds model with your CPA so the headline number translates to a real number.

For the full 27-point version, download the Hospice Owner’s Pre-Sale Readiness Checklist below.

Frequently asked questions about selling a hospice in 2026

How are hospice agencies valued in 2026?

As of April 2026, hospice agencies typically sell for 5x–8x adjusted EBITDA or 0.7x–1.4x trailing revenue. Multiples are driven by ADC, payer and level-of-care mix, length-of-stay distribution, Medicare cap exposure, HOPE/HQRP performance, referral concentration, and management depth. See the multiples table above for ranges by ADC tier.

Will the April 2026 fraud crackdown hurt my hospice’s sale price?

For clean operators, the suspension of 447 hospices is more likely to lift your price than lower it. Buyers are paying measurable premiums for documentably clean books while pulling back from anything with audit, SFP, or LOS outliers. This is the strongest “flight to quality” window for hospice M&A in five years.

How long does it take to sell a hospice agency?

Plan for 6–9 months from advisor engagement to close. The Medicare 855A CHOW filing alone takes 60–120 days. Add 60–90 days for active UPIC review, complex corporate structure, or multi-site licensure.

Can I sell my hospice during a Medicare audit or UPIC review?

Yes, but the buyer pool narrows and structures change. Buyers will require disclosure, escrow holdbacks, and often an indemnification reserve. Some PE platforms will pause until the review closes; strategics with strong compliance functions may proceed with appropriate protections. Engage advisor and counsel early — the right answer depends on the audit type, severity, and stage.

Who buys hospice agencies in 2026?

The 2026 buyer landscape includes PE-backed platform operators, regional consolidators expanding state by state, hospital and health-system home-based-care arms, and independent strategics doing single-state add-ons. Vallexa Advisors maintains a vetted, NDA-bound buyer network across all four categories.

What is the Special Focus Program (SFP) and why does it matter for a sale?

The SFP is CMS’s enforcement designation for the worst-performing hospices. Placement triggers enhanced surveys, civil monetary penalties, and potential termination of Medicare certification. In 2026, SFP placement is treated by virtually every buyer’s diligence team as a deal-killer until cleared. Confirming you are not on the SFP list is now a standard pre-LOI attestation.

Do I need an M&A advisor to sell my hospice?

You can sell without one, but you will almost always leave 1x–2x EBITDA on the table. A healthcare-only M&A advisor runs a confidential auction across a vetted buyer network, normalizes EBITDA, builds the data room, manages the CHOW, and protects the relationship with your staff and referral sources. At Vallexa Advisors, fees are 100% success-based — you pay only at close.

What is my hospice worth?

Your hospice’s value is a function of normalized EBITDA, ADC, payer and level-of-care mix, length-of-stay distribution, Medicare cap history, HOPE/HQRP performance, and referral network strength. The fastest path to a credible answer is a complimentary confidential valuation from Vallexa Advisors, built on the same model we apply to live transactions.

Is my hospice too small to sell?

Probably not. Vallexa regularly closes single-site hospices in the 30–60 ADC range, particularly in geographies attractive to regional consolidators. Below 30 ADC, the buyer pool narrows and asset-only structures become more common — but a sale is almost always still possible.

Vallexa Advisors hospice resources

• How to accurately value and maximize the worth of a hospice business
• 2026 Hospice & Home Health Valuation Multiples Report (U.S. market)
• How to sell a hospice or home health agency
• Hospice valuation tools for business owners
• How the 2026 Final Rule and HOPE Tool shape hospice valuation
• Current Vallexa hospice and home health listings
• Healthcare industries Vallexa serves
• Meet the Vallexa Advisors team

---

About the author

Jason Atty is Managing Director at Vallexa Advisors, a healthcare-only M&A firm specializing in hospice, home health, home care, and behavioral health transactions. Jason brings 18+ years of healthcare M&A experience advising owners on confidential sale processes, valuation, and post-close transitions. Vallexa runs a 5-step confidential process built on a vetted national buyer network, with 100% success-based fees.

Sources & further reading

• Home Health Care News — Feds Suspend 23 Home Health Orgs, 447 Hospices Over $600M Medicare Fraud (April 2026)
• Home Health Care News — Fraud Migrating From Hospice to Home Health, Witness Warns Congress (April 2026)
• Home Health Care News — Hospice Fraud Trends Highlight Risk for At-Home Care Providers in Expanding Enforcement Net (April 2026)
• CMS — Hospice Special Focus Program (SFP)
• CMS — HOPE Assessment Tool
• HHS Office of Inspector General

This article is published for informational purposes only and does not constitute legal, tax, accounting, or investment advice. Every transaction is unique. Engage qualified counsel and a CPA before making material decisions. Last updated April 27, 2026.

How to Value and Sell a Home Care Business in 2026